Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 199 participants.
Also called NCT02289963
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 199 participants
- Sponsor
- Registry
-
NCT02289963
-
- Other papers using this trial's data
- A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT)
- A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT02289963. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-04 (actual). Results posted on 2017-06-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Placebo (for Alirocumab)
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Lipid-Modifying Therapy (LMT)
- Lead sponsor
- Sanofi
- Collaborator
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct02289963- Content hash
1cf61292bbbd2827b6293dc7334e5f378a818fcf57863dcf157b8ec043c3c137